Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
Kim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst...
https://pubmed.ncbi.nlm.nih.gov/24782230/Actively Recruiting
Led by Murdoch Childrens Research Institute · Updated on 2026-05-05
50
Participants Needed
2
Research Sites
17 weeks
Total Duration
Researchers are investigating targeted drug therapies for patients with vascular malformations that are resistant to standard treatments or for whom standard treatments are unsuitable. These vascular malformations are classified as either slow-flow or fast-flow types, driven by genetic changes in two specific signalling pathways. This phase II open-label trial aims to evaluate the effects of 48 weeks of treatment using either alpelisib for slow-flow vascular malformations with PI3K pathway mutations or mirdametinib for fast-flow vascular malformations with MAPK pathway mutations. Participants are divided into two treatment groups based on their vascular malformation type and genetic mutation. Those with slow-flow malformations and PI3K pathway mutations will receive alpelisib, an oral PI3-kinase inhibitor, for 48 weeks followed by a 24-week follow-up. Those with fast-flow malformations and MAPK pathway mutations will receive mirdametinib, an investigational oral MEK inhibitor, also for 48 weeks followed by 24 weeks of follow-up. Both treatments are given as monotherapy and involve genetic testing before enrollment to confirm mutations. Throughout the study, participants will undergo various assessments including symptom evaluations using the Vascular Malformation Patient Specific Outcome Measure VM-PSOM and OVAMA questionnaires, MRI scans to measure lesion size, and monitoring for adverse events. The primary outcome is the improvement in the most significant symptom after 48 weeks of treatment. Follow-up visits continue for 24 weeks after treatment ends to monitor ongoing effects and safety. The total participation duration for each patient is approximately 72 weeks.
CONDITIONS
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
M
Michelle de Silva, PhD
T
Tony Penington, MBBS, FRACS
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Murdoch Childrens Research Institute
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 48 weeks
Participants receive targeted oral therapy specific to their vascular malformation type for 48 weeks.
Visits occur throughout the 48-week treatment period as scheduled by the study team
Duration - 24 weeks
Participants are monitored for safety and treatment effects for 24 weeks after completing therapy.
Visits occur during the 24-week follow-up period as scheduled by the study team
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Kim M Keppler-Noreuil, Julie C Sapp, Marjorie J Lindhurst...
https://pubmed.ncbi.nlm.nih.gov/24782230/Lara Al-Olabi, Satyamaanasa Polubothu, Katherine Dowsett...
https://pubmed.ncbi.nlm.nih.gov/29461977/Jennifer Hammer, Emmanuel Seront, Steven Duez...
https://pubmed.ncbi.nlm.nih.gov/30373605/Shannon M Smith, Robert H Dworkin, Dennis C Turk...
https://pubmed.ncbi.nlm.nih.gov/32520773/Robert Roskoski
https://pubmed.ncbi.nlm.nih.gov/22569528/E A Eisenhauer, P Therasse, J Bogaerts...
https://pubmed.ncbi.nlm.nih.gov/19097774/R Hoshino, Y Chatani, T Yamori...
https://pubmed.ncbi.nlm.nih.gov/9989833/Quitterie Venot, Thomas Blanc, Smail Hadj Rabia...
https://pubmed.ncbi.nlm.nih.gov/29899452/Denise M Adams, Cameron C Trenor, Adrienne M Hammill...
https://pubmed.ncbi.nlm.nih.gov/26783326/Paul A Harris, Robert Taylor, Robert Thielke...
https://pubmed.ncbi.nlm.nih.gov/18929686/Murdoch Childrens Research Institute
Lead Sponsor
Peter MacCallum Cancer Centre, Australia
Collaborating Sponsor